Efficacy of the Port Delivery System With Ranibizumab in Patients With Neovascular AMD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results
Ophthalmology 2023 Mar 02;[EPub Ahead of Print], C Regillo, B Berger, L Brooks, WL Clark, R Mittra, CC Wykoff, NF Callaway, S DeGraaf, HT Ding, AE Fung, S Gune, S Le Pogam, R Smith, JR Willis, G BarteselliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.